Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Duloxetine vs Placebo in the Treatment of General Anxiety
- Conditions
- Anxiety
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 327
- Registration Number
- NCT00475969
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Indianapolis, Indiana, United States
A Study of Enzastaurin in Participants With Follicular Lymphoma
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT00475644
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 228
- Registration Number
- NCT00471354
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Tao-Yuan, Taiwan
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 108
- Registration Number
- NCT00466440
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Sisto, Italy
A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2009-12-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 51
- Registration Number
- NCT00461786
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Philadelphia, Pennsylvania, United States
A Study of Enzastaurin in Patients With Leukemia
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2009-03-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT00452257
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
- Conditions
- Non-Small Cell Lung CancerMalignant Solid Tumor
- Interventions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 65
- Registration Number
- NCT00452413
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, United States
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 101
- Registration Number
- NCT00451178
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Crosse, Wisconsin, United States
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 156
- Registration Number
- NCT00451555
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
A Study for Patients With Type 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT00447213
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan